Cardiff Oncology earnings were -$40.9M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest CRDF earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$11.8M, up 17.6% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, CRDF reported annual earnings of -$41.5M, with 7.1% growth.
What were Cardiff Oncology's earnings last quarter?
On CRDF's earnings call on Invalid Date, Cardiff Oncology (NASDAQ: CRDF) reported Q2 2024 earnings per share (EPS) of -$0.26, up 4% year over year. Total CRDF earnings for the quarter were -$11.78 million. In the same quarter last year, Cardiff Oncology's earnings per share (EPS) was -$0.25.
As of the last Cardiff Oncology earnings report, Cardiff Oncology is currently losing money. Cardiff Oncology's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$40.86 million, a 3.07% increase year over year.
What was CRDF's earnings growth in the past year?
As of Cardiff Oncology's earnings date in Invalid Date, Cardiff Oncology's earnings has grown year over year. CRDF earnings in the past year totalled -$40.88 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.